8-K: Trustfeed Corp. Licenses Key Intellectual Property for Drug Delivery

Trustfeed Corp. has secured a non-exclusive, worldwide license for intellectual property related to the delivery of several key pharmaceutical ingredients.

Summary

• Trustfeed Corp. has entered into a Know How and Patent License Agreement with Pinata Holdings, Inc. to license intellectual property rights for the delivery of products containing metformin, sumatriptan, semaglutide, liraglutide, and sildenafil.
• The license is worldwide, non-exclusive, and non-transferable, but allows for sub-licensing.
• Trustfeed will pay Pinata a royalty ranging from 10% to 20% of net sales from products using the licensed IP.
• The agreement has a perpetual term, but can be terminated for material breach or with 180 days' notice.
• Trustfeed intends to use this IP in products manufactured and distributed after its planned acquisition of Polomar Specialty Pharmacy, LLC.
• Pinata is an affiliate of CWR 1, LLC, Trustfeed's majority shareholder, through common ownership.

Sentiment

Score: 7

Explanation: The agreement is a positive step for Trustfeed, providing access to valuable IP, but the non-exclusivity and royalty obligations temper the overall sentiment. The risks associated with the merger and patent approvals also contribute to a moderate positive sentiment.

Positives

• The license provides Trustfeed with access to valuable intellectual property for key pharmaceutical ingredients.
• The worldwide scope of the license allows for broad market reach.
• The perpetual term of the agreement provides long-term access to the technology.
• The ability to sub-license the technology provides flexibility for expansion.

Negatives

• The royalty payments, ranging from 10% to 20% of net sales, could impact profitability.
• The license is non-exclusive, meaning other companies could potentially use similar technology.
• The agreement can be terminated with 180 days' notice, creating some uncertainty.

Risks

• There is a risk that Pinata may not be granted the pending patents under the IP Rights.
• Trustfeed's ability to effectively use the licensed IP to increase customer value and financial returns is not guaranteed.
• Integrating the IP into the existing Polomar business and realizing the anticipated benefits of the license is not certain.
• The pending merger between Trustfeed and Polomar may not be completed.
• The company faces other risks described in its annual report and other filings with the SEC.

Future Outlook

The company intends to utilize the licensed IP in products expected to be manufactured and distributed after its planned acquisition of Polomar Specialty Pharmacy, LLC. The company cautions that forward-looking statements are subject to risks and uncertainties.

Management Comments

• It is the Company's intention to utilize the IP Rights in products expected to be manufactured and distributed by it subsequent to its planned acquisition of Polomar Specialty Pharmacy, LLC.

Industry Context

This agreement reflects a trend in the pharmaceutical industry where companies seek to enhance their product offerings through licensing intellectual property related to drug delivery and formulations. The specific ingredients targeted by the license are commonly used in treatments for diabetes, migraines, and erectile dysfunction, indicating a focus on established markets.

Comparison to Industry Standards

• Licensing agreements are common in the pharmaceutical industry, with royalty rates varying based on the exclusivity, market potential, and stage of development of the technology.
• The royalty rates of 10% to 20% are within the typical range for non-exclusive licenses, but the specific rates for each ingredient will impact the overall financial implications.
• Companies like Teva Pharmaceuticals and Mylan (now Viatris) frequently engage in licensing agreements to expand their product portfolios, often focusing on generic versions of existing drugs.
• The perpetual term of the agreement is less common, as many licenses have a defined term, but this may reflect the nature of the underlying technology and the relationship between the parties.

Related Party Transactions

• Pinata is an affiliate of CWR 1, LLC, Trustfeed's majority shareholder, through common ownership.

Stakeholder Impact

• Shareholders may view this agreement positively as it provides access to new technology and potential revenue streams.
• Employees may be impacted by the integration of the new technology and the potential expansion of the company's operations.
• Customers may benefit from new and improved products resulting from the licensed technology.
• Suppliers may see increased demand for materials used in the production of the new products.

Next Steps

• Trustfeed will proceed with the planned acquisition of Polomar Specialty Pharmacy, LLC.
• Trustfeed will integrate the licensed IP into its product development and manufacturing processes.
• Trustfeed will begin manufacturing and distributing products utilizing the licensed IP.

Key Dates

Keywords

intellectual property, patent license, pharmaceuticals, drug delivery, metformin, sumatriptan, semaglutide, liraglutide, sildenafil, royalty, acquisition, Polomar Specialty Pharmacy